Reata Pharmaceuticals, Inc. to Report Third Quarter 2020 Financial Results and Provide an Update on Development Programs on N...
November 02 2020 - 5:30PM
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,”
or “we”), a clinical-stage biopharmaceutical company, today
announced that it will report financial results and provide an
update on its development programs before the market opens on
November 9, 2020.
Reata’s management will host a conference call on
November 9, 2020 at 8:00 a.m. ET. The conference call will be
accessible by dialing (844)348-3946 (toll-free domestic) or
(213)358-0892 (international) using the access code: 2896858. The
webcast link is https://edge.media-server.com/mmc/p/z6fgbcwf.
Third quarter 2020 financial results to be
discussed during the call will be included in an earnings press
release that will be available on the company’s website shortly
before the call at http://reatapharma.com/investors/ and will be
available for 12 months after the call. The audio recording and
webcast will be accessible for at least 90 days after the event at
http://reatapharma.com/investors/.
About Reata Pharmaceuticals,
Inc.
Reata is a clinical-stage biopharmaceutical company
that develops novel therapeutics for patients with serious or
life-threatening diseases by targeting molecular pathways involved
in the regulation of cellular metabolism and inflammation. Reata’s
two most advanced clinical candidates, bardoxolone methyl
(“bardoxolone”) and omaveloxolone, target the important
transcription factor Nrf2 that promotes the resolution of
inflammation by restoring mitochondrial function, reducing
oxidative stress, and inhibiting pro-inflammatory signaling.
Bardoxolone and omaveloxolone are investigational drugs,
and their safety and efficacy have not been established by any
agency.
Contact:Reata Pharmaceuticals,
Inc.(972) 865-2219http://reatapharma.com
Investors:Vinny
JindalVice President, Investor Relations and Corporate
Communications (469)
374-8721ir@reatapharma.comhttp://reatapharma.com/contact-us/
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Sep 2023 to Sep 2024